Merck&Co will announce its quarterly financial results in 6 days. Traders should take this into account as the share price often fluctuates around this time period.
Compiled here, all relevant comments and discussions regarding the MRK stock. Please note that all comments included here have met Investing.com's Comment Guidelines.
What is your sentiment on Merck&Co?
or
Market is currently closed. Voting is open during market hours.
All Comments
(380)
At this point a small adjustment is logical.
0
Aehr test systems up the moon
0
Good company, but the price is way too high in light of its growth prospect and economic condition.
1
Breaking out . Watch for $120 Silvia,those dang "mrons and thier baseless predictions"
1
why would anyone be buying at this inflated level. This has run its course.
1
completely inflated... anyone buying this will get rekt like crazy.. these stocks are bitcoin in november 2021..
4
Wow. Compare big pharma with strong cash flow to cryptopoop. Good luck man, you will need it.
0
best stock ever
1
Hi guys, can i know the target price for this share?
0
Bought years ago, 1995 at $22. Long term investing works.
0
hom many shares did you buy 10
1
about 250
0
initially, then some more later
0
Bought this year's ago for $55. Think I will hold it forever.
1
how many shares did you buy 50
2
you should of bought shares instead of calling me a mron
0
wow
1
They are selling a lot of finasteride for mens hairloss.
ma e' sui massimi da sempre? che t.p. si puo' immaginare a questo punto ?
2
🚀🚀🚀🚀🚀🚀🚀🌜
0
Good, even great reasults in first quater of 2022.Let's hope to go back to 86-87 territory
0
The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention.
0
The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.
0
The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.
0
It was 22 in 1995. Do the math and look at the products.